DexCom, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-75.7% vs price
Base Case (Median)
-60.8% vs price
Bull Case (75th pct.)
-27.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $9.58 | -89.2% | High (40%) |
| PE Comparable | $56.30 | -36.6% | Medium (25%) |
| Growth Trajectory DCF | $109.72 | 23.6% | Medium (20%) |
| Graham Number | $20.02 | -77.5% | Medium (40%) |
| EV/EBITDA | $34.82 | -60.8% | Medium (20%) |
| EV/FCF | $72.01 | -18.9% | Medium (20%) |
| Earnings Power Value | $23.15 | -73.9% | Medium (50%) |
Based on 7 out of 8 methods, DXCM appears overvalued at the current price of $88.76. The base case fair value of $34.82 implies 60.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.